Genprex (GNPX) Financials

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Genprex

Annual Income Statements for Genprex

This table shows Genprex's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Consolidated Net Income / (Loss)
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Net Income / (Loss) Continuing Operations
-4.13 -3.32 -12 -11 -18 -21 -24 -31 -21 -16
Total Pre-Tax Income
-4.13 -3.32 -12 -11 -18 -21 -24 -31 -21 -16
Total Operating Income
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
4.13 3.31 12 11 18 21 24 31 21 16
Selling, General & Admin Expense
3.78 3.02 11 8.70 11 12 12 13 11 6.09
Research & Development Expense
0.35 0.29 0.97 1.97 7.30 8.97 12 18 11 9.43
Depreciation Expense
0.00 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.00
Total Other Income / (Expense), net
0.00 -0.00 -0.01 0.03 0.02 0.01 0.09 0.20 0.00 -0.74
Other Income / (Expense), net
- -0.00 - - - - - -0.02 0.00 -0.74
Other Gains / (Losses), net
- - - - - - - - 0.06 0.03
Preferred Stock Dividends Declared
- - - - - - - 0.00 0.28 0.00
Basic Earnings per Share
($0.38) ($0.29) ($0.90) ($0.66) ($0.51) ($0.44) ($19.80) ($22.56) ($266.89) ($17.40)
Weighted Average Basic Shares Outstanding
10.83M 11.50M 13.77M 16.03M 35.52M 47.10M 1.20M 1.37M 80.14K 932.73K
Weighted Average Diluted Shares Outstanding
10.83M 11.50M 13.77M 16.03M 35.52M 47.10M 51.97M 1.91M 24.15M 9.04M
Weighted Average Basic & Diluted Shares Outstanding
10.83M 11.50M 13.77M 16.03M 35.52M 47.10M 51.97M 1.91M 24.15M 9.04M

Quarterly Income Statements for Genprex

This table shows Genprex's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-7.75 -5.93 -6.25 -6.50 -4.32 -4.33 -3.96 -4.67 -3.80 -3.79 -4.46
Consolidated Net Income / (Loss)
-7.75 -5.93 -5.97 -6.50 -4.32 -4.33 -3.96 -4.67 -3.80 -3.79 -4.46
Net Income / (Loss) Continuing Operations
-7.75 -5.93 -5.97 -6.50 -4.32 -4.33 -3.96 -4.67 -3.80 -3.79 -4.46
Total Pre-Tax Income
-7.75 -5.93 -5.97 -6.50 -4.32 -4.39 -3.97 -4.67 -3.80 -3.82 -4.49
Total Operating Income
-7.79 -5.97 -6.00 -6.52 -4.32 -4.34 -3.97 -4.68 -3.35 -3.52 -4.49
Total Gross Profit
0.00 -0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue
0.00 -0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
7.79 5.97 6.00 6.52 4.32 4.34 3.97 4.68 3.35 3.52 4.49
Selling, General & Admin Expense
3.17 2.25 2.72 4.85 1.57 1.50 1.43 2.18 1.15 1.32 1.75
Research & Development Expense
4.62 3.71 3.27 1.67 2.76 2.84 2.54 2.50 2.19 2.20 2.75
Depreciation Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net
0.04 0.04 0.03 0.02 0.01 -0.06 -0.00 0.01 -0.45 -0.30 0.00
Other Income / (Expense), net
-0.01 - 0.00 -0.00 -0.00 0.00 -0.00 0.00 -0.46 -0.28 0.00
Other Gains / (Losses), net
- - - - - - 0.00 - - - 0.03
Basic Earnings per Share
($5.36) ($4.34) ($3.86) ($3.00) ($61.65) ($54.04) ($12.98) ($0.17) ($5.00) ($4.06) ($0.64)
Weighted Average Basic Shares Outstanding
1.45M 1.37M 1.62M 2.16M 70.01K 80.14K 305.33K 27.59M 760.50K 932.73K 6.95M
Weighted Average Diluted Shares Outstanding
59.43M 1.91M 2.10M 2.59M 8.51M 24.15M 27.82M 33.47M 2.27M 9.04M 10.59M
Weighted Average Basic & Diluted Shares Outstanding
59.43M 1.91M 2.10M 2.59M 8.51M 24.15M 27.82M 33.47M 2.27M 9.04M 10.59M

Annual Cash Flow Statements for Genprex

This table details how cash moves in and out of Genprex's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
1.37 -1.44 8.44 -6.60 25 11 -18 -14 -5.14 6.23
Net Cash From Operating Activities
-1.25 -2.17 -6.85 -6.92 -14 -14 -18 -25 -18 -15
Net Cash From Continuing Operating Activities
-1.25 -2.17 -6.85 -6.92 -14 -14 -18 -25 -18 -15
Net Income / (Loss) Continuing Operations
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Consolidated Net Income / (Loss)
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Depreciation Expense
0.00 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.00
Non-Cash Adjustments To Reconcile Net Income
2.66 1.32 5.44 3.53 4.25 5.35 4.89 5.93 3.60 1.30
Changes in Operating Assets and Liabilities, net
0.22 -0.18 0.08 0.19 -0.26 1.01 1.20 0.18 -0.42 -0.38
Net Cash From Investing Activities
-0.09 -0.06 -0.10 -0.95 -2.34 -0.08 -0.06 -0.07 0.77 0.00
Net Cash From Continuing Investing Activities
-0.09 -0.06 -0.10 -0.95 -2.34 -0.08 -0.06 -0.07 0.77 0.00
Sale of Property, Plant & Equipment
- - - - - - 0.00 0.00 0.00 0.00
Divestitures
- - - - - - - - 0.77 0.00
Net Cash From Financing Activities
2.71 0.79 15 1.27 42 26 0.01 11 12 22
Net Cash From Continuing Financing Activities
2.71 0.79 15 1.27 42 26 0.01 11 12 22
Issuance of Common Equity
2.71 0.79 15 1.27 42 26 0.01 11 12 22

Quarterly Cash Flow Statements for Genprex

This table details how cash moves in and out of Genprex's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
1.76 -4.97 1.48 -5.76 -0.97 0.11 1.87 -2.12 -0.24 6.73 10
Net Cash From Operating Activities
-4.74 -4.96 -5.30 -6.57 -2.19 -3.87 -4.16 -3.86 -3.19 -4.10 -3.14
Net Cash From Continuing Operating Activities
-4.74 -4.96 -5.30 -6.57 -2.19 -3.87 -4.16 -3.86 -3.19 -4.10 -3.14
Net Income / (Loss) Continuing Operations
-7.75 -5.93 -5.97 -6.50 -4.32 -4.33 -3.96 -4.67 -3.80 -3.79 -4.46
Consolidated Net Income / (Loss)
-7.75 -5.93 -5.97 -6.50 -4.32 -4.33 -3.96 -4.67 -3.80 -3.79 -4.46
Non-Cash Adjustments To Reconcile Net Income
1.27 1.69 0.33 2.40 0.63 0.25 0.39 0.53 0.40 -0.02 0.37
Changes in Operating Assets and Liabilities, net
1.74 -0.73 0.34 -2.47 1.50 0.22 -0.58 0.28 0.21 -0.29 0.95
Net Cash From Investing Activities
-0.02 -0.01 -0.02 0.79 - -0.00 0.00 - - - 0.00
Net Cash From Continuing Investing Activities
-0.02 -0.01 -0.02 0.79 - -0.00 0.00 - - - 0.00
Net Cash From Financing Activities
6.51 0.00 6.79 0.02 1.22 3.98 6.03 1.74 2.94 11 13
Net Cash From Continuing Financing Activities
6.51 0.00 6.79 0.02 1.22 3.98 6.03 1.74 2.94 11 13
Issuance of Common Equity
6.51 0.00 6.79 0.02 1.22 3.98 6.03 1.74 2.94 11 13

Annual Balance Sheets for Genprex

This table presents Genprex's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
1.91 1.26 9.27 3.53 31 43 25 11 4.12 10
Total Current Assets
1.64 0.19 8.85 2.98 28 39 21 7.53 2.08 8.36
Cash & Equivalents
1.60 0.16 8.60 2.00 27 39 21 6.74 1.60 7.83
Prepaid Expenses
0.03 0.02 0.24 0.17 0.38 0.51 0.48 0.79 0.48 0.53
Plant, Property, & Equipment, net
0.01 0.01 0.02 0.04 0.04 0.05 0.02 0.01 0.00 0.00
Total Noncurrent Assets
0.27 1.06 0.40 0.51 3.62 3.67 3.59 3.13 2.05 1.80
Other Noncurrent Operating Assets
0.03 0.76 0.02 0.02 3.02 3.03 2.89 2.36 2.05 1.80
Total Liabilities & Shareholders' Equity
1.91 1.26 9.27 3.53 31 43 25 11 4.12 10
Total Liabilities
0.29 0.83 0.39 0.51 0.45 1.59 2.81 3.25 2.50 2.20
Total Current Liabilities
0.29 0.83 0.39 0.51 0.45 1.59 2.81 3.25 2.50 2.17
Accounts Payable
0.29 0.63 0.30 0.44 0.19 0.97 0.44 1.40 1.07 0.74
Other Current Liabilities
0.00 0.20 0.09 0.07 0.26 0.61 2.37 1.86 1.43 1.43
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Other Noncurrent Operating Liabilities
0.00 0.00 0.00 0.00 - - - - 0.00 0.02
Commitments & Contingencies
0.00 0.00 0.00 0.00 - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1.62 0.43 8.88 3.02 31 41 22 7.42 1.62 7.96
Total Preferred & Common Equity
1.62 0.43 8.88 3.02 31 41 22 7.42 1.62 7.96
Preferred Stock
- - - - - - - 0.00 0.00 0.00
Total Common Equity
1.62 0.43 8.88 3.02 31 41 22 7.42 1.62 7.96
Common Stock
16 18 39 44 89 120 125 141 156 179
Retained Earnings
-14 -17 -30 -40 -58 -79 -103 -134 -155 -171

Quarterly Balance Sheets for Genprex

This table presents Genprex's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
17 13 6.60 3.91 6.01 3.83 3.56 20
Total Current Assets
13 9.23 4.39 1.92 4.16 2.06 1.72 19
Cash & Equivalents
12 8.22 2.46 1.49 3.47 1.35 1.10 18
Prepaid Expenses
1.15 1.01 1.94 0.43 0.70 0.71 0.61 0.75
Plant, Property, & Equipment, net
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
3.78 3.33 2.21 1.99 1.85 1.77 1.85 1.50
Other Noncurrent Operating Assets
3.01 2.54 2.21 1.99 1.85 1.77 1.85 1.50
Total Liabilities & Shareholders' Equity
17 13 6.60 3.91 6.01 3.83 3.56 20
Total Liabilities
4.34 3.81 2.26 2.24 2.14 2.44 2.79 3.38
Total Current Liabilities
4.34 3.81 2.26 2.24 2.14 2.44 2.55 3.35
Accounts Payable
1.18 2.15 1.17 1.30 1.53 0.93 1.62 1.66
Other Current Liabilities
3.16 1.66 1.08 0.94 0.62 1.51 0.93 1.70
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.02
Other Noncurrent Operating Liabilities
- - - - - - 0.24 0.02
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
12 8.76 4.35 1.66 3.87 1.39 0.77 17
Total Preferred & Common Equity
12 8.76 4.35 1.66 3.87 1.39 0.77 17
Preferred Stock
0.00 - - - 0.00 0.00 0.00 0.00
Total Common Equity
12 8.76 4.35 1.66 3.87 1.39 0.77 17
Common Stock
140 148 150 152 163 165 168 192
Retained Earnings
-128 -140 -146 -150 -159 -163 -167 -175

Annual Metrics And Ratios for Genprex

This table displays calculated financial ratios and metrics derived from Genprex's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 358,676.00 15,072,559.00 15,847,855.00 39,618,722.00 47,808,570.00 48,025,324.00 59,434,822.00 8,508,068.00 2,270,346.00
DEI Adjusted Shares Outstanding
0.00 179.00 7,536.00 7,924.00 19,809.00 23,904.00 24,013.00 29,717.00 170,161.00 2,270,346.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -18,514.84 -1,641.76 -1,344.62 -905.79 -864.50 -988.66 -1,038.48 -125.69 -7.15
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 19.86% -273.24% 13.66% -68.13% -15.10% -15.29% -30.48% 31.85% 23.20%
EBIT Growth
0.00% 19.80% -273.05% 13.60% -68.14% -15.08% -15.29% -30.40% 31.86% 23.23%
NOPAT Growth
0.00% 19.84% -273.26% 13.60% -68.14% -15.08% -15.29% -30.32% 31.82% 26.72%
Net Income Growth
0.00% 19.80% -273.32% 13.88% -68.40% -15.17% -14.88% -29.99% 31.59% 23.13%
EPS Growth
0.00% 23.68% -210.34% 26.67% 22.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
0.00% -73.97% -215.28% -1.05% -101.41% -2.51% -23.36% -40.39% 27.55% 14.57%
Free Cash Flow Firm Growth
0.00% 0.00% -238.12% 5.18% -84.32% 10.75% -13.56% -37.41% 32.88% 22.51%
Invested Capital Growth
0.00% 1,084.26% 4.82% 264.38% 252.26% -26.38% -50.13% -48.61% -97.28% 608.41%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 100.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -29.00% 8.71% -18.50% -7.96% 0.72% 1.86% 7.15% 3.17%
EBIT Q/Q Growth
0.00% 0.00% -28.99% 8.69% -18.49% -7.95% 0.72% 1.87% 7.16% 3.17%
NOPAT Q/Q Growth
0.00% 0.00% -28.99% 8.69% -18.49% -7.95% 0.72% 1.93% 7.16% 5.00%
Net Income Q/Q Growth
0.00% 0.00% -28.77% 8.63% -18.52% -7.96% 0.95% 1.89% 7.04% 3.22%
EPS Q/Q Growth
0.00% 0.00% -25.00% 14.29% 1.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 22.68% -37.03% 4.69% -18.45% 4.51% -8.15% -1.72% 5.76% -7.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 8.66% -31.20% 7.59% 1.77% -1.48% 8.91% -0.48%
Invested Capital Q/Q Growth
0.00% 0.00% 60.83% 3.91% 87.56% -15.79% -33.04% 14.24% -89.53% 139.05%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 99.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.70% 99.83%
Interest Burden Percent
100.00% 100.05% 100.07% 99.74% 99.90% 99.98% 99.62% 99.31% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-254.31% -322.79% -265.79% -179.00% -105.73% -57.25% -74.71% -207.88% -467.24% -338.74%
Cash Return on Invested Capital (CROIC)
0.00% -1,768.49% -3,165.93% -1,263.18% -656.10% -433.00% -773.74% -2,110.40% -4,062.15% -14,678.64%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-254.31% -322.79% -265.79% -179.00% -105.73% -57.25% -74.71% -207.88% -467.24% -338.74%
Return on Equity Simple (ROE_SIMPLE)
-254.31% -773.30% -139.31% -352.39% -58.04% -50.06% -106.58% -416.11% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.89 -2.32 -8.65 -7.48 -13 -14 -17 -22 -15 -11
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-77.37% -112.90% -84.86% -59.92% -36.63% -18.79% -23.70% -65.87% -150.83% -113.82%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -293.13% -914.85% -136.41%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.13 -3.31 -12 -11 -18 -21 -24 -31 -21 -16
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
3.94 0.00 1.87 1.68 5.32 1.52 3.13 1.84 4.47 0.50
Price to Tangible Book Value (P/TBV)
4.62 0.00 1.95 2.00 5.42 1.54 3.23 2.06 4.47 0.50
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
212.54 0.00 28.47 3.01 38.12 9.06 36.86 10.21 305.15 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.99 -0.86 -0.94 -0.89 -0.86 -0.91 -0.94 -0.93 -0.92 -0.98
Leverage Ratio
1.18 1.54 1.13 1.08 1.03 1.03 1.07 1.20 1.64 1.49
Compound Leverage Factor
1.18 1.54 1.13 1.07 1.03 1.03 1.07 1.20 1.64 1.49
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-3.21 0.00 17.84 -19.21 215.42 20.58 6.89 -24.15 -67.88 -27.03
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
5.74 0.23 22.81 5.83 61.47 24.69 7.64 2.31 0.83 3.84
Quick Ratio
5.64 0.20 22.20 3.92 60.61 24.37 7.47 2.07 0.64 3.60
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -2.56 -8.67 -8.22 -15 -14 -15 -21 -14 -11
Operating Cash Flow to CapEx
-25,075.59% -36,875.43% -30,517.20% -20,733.36% -79,338.91% -45,062.85% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -1,356.29 -228.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 -1,148.99 -180.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 -1,152.11 -180.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.02 0.27 0.28 1.02 3.60 2.65 1.32 0.68 0.02 0.13
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 0.24 0.01 0.74 2.58 -0.95 -1.33 -0.64 -0.66 0.11
Enterprise Value (EV)
4.80 0.00 7.98 3.07 137 24 49 6.93 5.64 -3.86
Market Capitalization
6.40 0.00 17 5.07 164 63 70 14 7.25 3.97
Book Value per Share
$0.15 $1.19 $0.59 $0.19 $0.78 $0.86 $0.46 $0.12 $0.19 $3.51
Tangible Book Value per Share
$0.13 $0.36 $0.56 $0.16 $0.77 $0.85 $0.45 $0.11 $0.19 $3.51
Total Capital
1.62 0.43 8.88 3.02 31 41 22 7.42 1.62 7.96
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1.60 -0.16 -8.60 -2.00 -27 -39 -21 -6.74 -1.60 -7.83
Capital Expenditures (CapEx)
0.00 0.01 0.02 0.03 0.02 0.03 0.00 -0.00 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.25 -0.80 -0.14 0.46 -0.07 -1.07 -2.29 -2.46 -2.03 -1.65
Debt-free Net Working Capital (DFNWC)
1.35 -0.64 8.46 2.47 27 38 19 4.28 -0.43 6.18
Net Working Capital (NWC)
1.35 -0.64 8.46 2.47 27 38 19 4.28 -0.43 6.18
Net Nonoperating Expense (NNE)
1.24 1.00 3.72 3.18 5.37 6.20 7.06 9.12 6.29 5.37
Net Nonoperating Obligations (NNO)
-1.60 -0.16 -8.60 -2.00 -27 -39 -21 -6.74 -1.60 -7.83
Total Depreciation and Amortization (D&A)
0.00 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($15.20) ($11.60) ($36.00) ($26.40) ($20.40) ($16.80) $0.00 ($22.56) ($267.00) ($17.40)
Adjusted Weighted Average Basic Shares Outstanding
270.87K 287.50K 388.42K 821.25K 1.08M 1.20M 0.00 1.37M 80.12K 932.73K
Adjusted Diluted Earnings per Share
($15.20) ($11.60) ($36.00) ($26.40) ($20.40) ($16.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
270.87K 287.50K 388.42K 821.25K 1.08M 1.20M 0.00 1.91M 483.06K 9.04M
Adjusted Basic & Diluted Earnings per Share
($15.20) ($11.60) ($36.00) ($26.40) ($20.40) ($16.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
270.87K 287.50K 344.28K 400.68K 888.07K 1.18M 0.00 1.91M 483.06K 9.04M
Normalized Net Operating Profit after Tax (NOPAT)
-2.89 -2.32 -8.65 -7.48 -13 -14 -17 -22 -15 -11
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -1,753.52 -325.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 -1,226.80 -227.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 -1,756.64 -326.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 -1,229.91 -228.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Genprex

This table displays calculated financial ratios and metrics derived from Genprex's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
59,409,822.00 59,434,822.00 1,910,441.00 2,098,698.00 2,588,546.00 8,508,068.00 24,152,848.00 27,821,136.00 33,466,784.00 2,270,346.00 9,044,856.00
DEI Adjusted Shares Outstanding
29,705.00 29,717.00 38,209.00 41,974.00 51,771.00 170,161.00 483,057.00 556,423.00 669,336.00 2,270,346.00 9,044,856.00
DEI Earnings Per Adjusted Shares Outstanding
-260.84 -199.52 -163.47 -154.76 -83.37 -25.45 -8.21 -8.40 -5.68 -1.67 -0.49
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-26.47% 9.26% 35.32% 18.89% 44.55% 27.34% 33.78% 28.16% 12.06% 12.25% -13.21%
EBIT Growth
-26.40% 9.29% 35.32% 18.90% 44.56% 27.37% 33.81% 28.18% 12.08% 12.26% -13.21%
NOPAT Growth
-26.19% 9.29% 35.27% 18.91% 44.47% 27.35% 33.81% 28.17% 22.61% 18.85% -13.22%
Net Income Growth
-26.14% 9.11% 35.14% 18.60% 44.30% 26.96% 33.58% 28.03% 11.97% 12.48% -12.54%
EPS Growth
0.00% 9.11% 0.00% 0.00% 0.00% 26.96% 0.00% 0.00% 0.00% 92.49% 0.00%
Operating Cash Flow Growth
-4.70% -9.18% 23.58% 18.97% 53.84% 22.05% 21.45% 41.18% -45.81% -5.91% 24.58%
Free Cash Flow Firm Growth
-29.40% -7.86% 1.87% 18.82% 35.93% 32.84% 39.14% 67.04% 29.86% -8.46% 38.32%
Invested Capital Growth
-69.88% -48.61% 34.19% -9.96% -70.26% -97.28% -25.96% -97.65% -289.89% 608.41% -380.08%
Revenue Q/Q Growth
-100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
2.96% 23.49% -0.49% -8.72% 33.67% -0.26% 8.42% -17.95% 18.80% -0.04% -18.16%
EBIT Q/Q Growth
2.96% 23.48% -0.48% -8.71% 33.67% -0.24% 8.43% -17.95% 18.80% -0.04% -18.16%
NOPAT Q/Q Growth
3.13% 23.35% -0.48% -8.70% 33.67% -0.28% 8.45% -17.95% 28.53% -5.16% -27.73%
Net Income Q/Q Growth
2.91% 23.48% -0.67% -8.83% 33.56% -0.34% 8.45% -17.92% 18.73% 0.24% -17.72%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
41.59% -4.83% -6.73% -24.00% 66.73% -77.02% -7.55% 7.14% 17.52% -28.58% 23.42%
Free Cash Flow Firm Q/Q Growth
24.08% 13.17% -22.61% -0.44% 40.08% 8.98% -11.10% 45.61% -27.52% -40.75% 36.81%
Invested Capital Q/Q Growth
-71.64% 14.24% -20.51% 249.64% -90.63% -89.53% 2,060.14% -88.90% -856.48% 139.05% -954.05%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.04% 100.00% 100.00% 100.00% 98.57% 99.88% 100.00% 100.00% 99.30% 99.29%
Interest Burden Percent
99.34% 99.31% 99.54% 99.65% 99.81% 101.36% 100.00% 99.85% 99.94% 100.37% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -207.88% -202.83% -318.88% -325.11% -467.24% -302.69% -602.64% -1,378.61% -338.74% -160.84%
Cash Return on Invested Capital (CROIC)
-1,619.97% -2,110.40% -4,160.79% -913.17% -4,033.68% -4,062.15% -2,824.60% -1,064.28% 0.00% -14,678.64% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% -207.88% -202.83% -318.88% -325.11% -467.24% -302.69% -602.64% -1,378.61% -338.74% -160.84%
Return on Equity Simple (ROE_SIMPLE)
-255.62% 0.00% -315.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-5.45 -4.18 -4.20 -4.56 -3.03 -3.04 -2.78 -3.28 -2.34 -2.46 -3.15
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-12.34% -12.65% -13.47% -31.14% -19.54% -31.07% -20.30% -73.45% -112.45% -28.14% -12.23%
Return On Investment Capital (ROIC_SIMPLE)
- -56.33% -47.94% -105.00% -181.77% -187.33% -71.84% -235.57% -305.04% -30.94% -18.58%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-7.80 -5.97 -6.00 -6.52 -4.32 -4.33 -3.97 -4.68 -3.80 -3.80 -4.49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.80 -5.96 -5.99 -6.52 -4.32 -4.33 -3.97 -4.68 -3.80 -3.80 -4.49
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.91 1.84 0.51 0.91 0.56 4.47 1.53 4.56 7.38 0.50 0.97
Price to Tangible Book Value (P/TBV)
2.03 2.06 0.56 0.91 0.56 4.47 1.53 4.56 7.38 0.50 0.97
Price to Revenue (P/Rev)
10,625.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
19.77 10.21 0.00 0.79 0.00 305.15 6.15 112.59 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
5,321.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.94 -0.93 -0.97 -0.76 -0.94 -0.92 -0.93 -0.66 -1.07 -0.98 -1.03
Leverage Ratio
1.17 1.20 1.32 1.37 1.47 1.64 1.47 1.82 3.07 1.49 1.27
Compound Leverage Factor
1.16 1.20 1.31 1.37 1.47 1.66 1.47 1.82 3.07 1.50 1.27
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-8.43 -16.38 -15.92 -32.80 -57.42 -54.40 -37.10 -62.38 -68.31 -22.99 -9.01
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.96 2.31 2.42 1.95 0.86 0.83 1.94 0.84 0.67 3.84 5.61
Quick Ratio
2.70 2.07 2.16 1.09 0.66 0.64 1.62 0.55 0.43 3.60 5.38
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-4.07 -3.54 -4.34 -4.35 -2.61 -2.37 -2.64 -1.44 -1.83 -2.58 -1.63
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% -386,943,000.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.59 0.68 0.54 1.89 0.18 0.02 0.40 0.04 -0.34 0.13 -1.12
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-1.38 -0.64 0.14 -0.21 -0.42 -0.66 -0.14 -1.84 -0.51 0.11 -1.52
Enterprise Value (EV)
12 6.93 -3.79 1.50 -0.55 5.64 2.46 4.99 4.57 -3.86 -1.68
Market Capitalization
23 14 4.43 3.96 0.94 7.25 5.92 6.34 5.67 3.97 16
Book Value per Share
$0.21 $0.12 $0.15 $2.07 $0.64 $0.19 $0.45 $0.05 $0.02 $3.51 $1.87
Tangible Book Value per Share
$0.19 $0.11 $0.13 $2.07 $0.64 $0.19 $0.45 $0.05 $0.02 $3.51 $1.87
Total Capital
12 7.42 8.76 4.35 1.66 1.62 3.87 1.39 0.77 7.96 17
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-12 -6.74 -8.22 -2.46 -1.49 -1.60 -3.47 -1.35 -1.10 -7.83 -18
Capital Expenditures (CapEx)
0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.19 -2.46 -2.80 -0.32 -1.81 -2.03 -1.45 -1.73 -1.94 -1.65 -2.60
Debt-free Net Working Capital (DFNWC)
8.52 4.28 5.42 2.14 -0.32 -0.43 2.02 -0.38 -0.84 6.18 15
Net Working Capital (NWC)
8.52 4.28 5.42 2.14 -0.32 -0.43 2.02 -0.38 -0.84 6.18 15
Net Nonoperating Expense (NNE)
2.30 1.75 1.77 1.93 1.29 1.30 1.19 1.40 1.46 1.33 1.32
Net Nonoperating Obligations (NNO)
-12 -6.74 -8.22 -2.46 -1.49 -1.60 -3.47 -1.35 -1.10 -7.83 -18
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
-144,582.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
385,821.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
385,821.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($5.20) ($173.60) ($3.69) ($3.00) ($61.50) ($2,702.00) ($13.00) ($0.17) ($5.00) ($4.06) ($0.64)
Adjusted Weighted Average Basic Shares Outstanding
1.45M 34.19K 1.62M 2.16M 70.00K 1.60K 305.31K 27.59M 760.50K 932.73K 6.95M
Adjusted Diluted Earnings per Share
$0.00 ($173.60) $0.00 $0.00 $0.00 ($2,702.00) $0.00 $0.00 $0.00 ($4.06) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
1.49M 47.76K 2.10M 2.59M 170.16K 483.06K 556.42K 33.47M 2.27M 9.04M 10.59M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($173.60) $0.00 $0.00 $0.00 ($2,702.00) $0.00 $0.00 $0.00 ($4.06) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.49M 47.76K 2.10M 2.59M 170.16K 483.06K 556.42K 33.47M 2.27M 9.04M 10.59M
Normalized Net Operating Profit after Tax (NOPAT)
-5.45 -4.18 -4.20 -4.56 -3.03 -3.04 -2.78 -3.28 -2.34 -2.46 -3.15
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Genprex (NASDAQ:GNPX) remains a development-stage biotechnology company with no meaningful operating revenue. The company reported zero revenue and zero gross profit in each of the available 2024–2026 income statements, leaving research and development and corporate expenses as the primary drivers of its results.

  • Operating cash burn improved to $3.1 million in Q1 2026, compared with $4.1 million in Q4 2025, $4.2 million in Q1 2025 and $5.3 million in Q1 2024.
  • The net loss of $4.5 million in Q1 2026 was narrower than the $6.0 million loss in Q1 2024 and the $7.7 million loss in Q3 2023, suggesting some improvement from the higher losses reported in earlier periods.
  • Genprex raised $13.4 million through common-stock issuance in Q1 2026, increasing cash and equivalents to $18.0 million from approximately $1.1 million at the end of Q3 2025.
  • The balance sheet strengthened following the financing, with total equity rising to $16.9 million at March 31, 2026, from just $0.8 million at September 30, 2025.
  • Current assets of $18.8 million substantially exceeded current liabilities of $3.4 million at the end of Q1 2026, providing a stronger near-term liquidity position than the company had during much of 2025.
  • Research and development spending was $2.7 million in Q1 2026, representing the majority of operating expenses and indicating that Genprex continues to prioritize development activities over commercialization.
  • The company reported no significant investing cash outflows in Q1 2026, and net property, plant and equipment was zero, reflecting a relatively asset-light operating structure.
  • Genprex has generated essentially no operating revenue across the reported periods, so its path to profitability remains dependent on successful clinical development, regulatory progress and eventual commercialization.
  • Operating expenses increased to $4.5 million in Q1 2026 from $3.5 million in Q4 2025, driven by higher selling, general and administrative expense and research and development spending.
  • The company continues to rely on equity financing to fund operations. Repeated stock issuances—including $10.8 million in Q4 2025 and $13.4 million in Q1 2026—can dilute existing shareholders, while retained earnings remained deeply negative at approximately -$175.5 million.

Overall, Genprex’s liquidity improved materially after its latest equity raise, and quarterly cash burn has moderated compared with earlier periods. However, the company remains unprofitable, has no recurring revenue, and continues to consume cash from operations. The latest cash balance provides additional funding capacity, but investors should closely monitor future financing activity, clinical-development spending and whether the company can advance its pipeline toward revenue generation without substantial additional dilution.

11/22/26 12:49 PM ETAI Generated. May Contain Errors.

Genprex Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Genprex's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Genprex's net income appears to be on a downward trend, with a most recent value of -$16.23 million in 2025, falling from -$4.13 million in 2016. The previous period was -$21.11 million in 2024. Find out what analysts predict for Genprex in the coming months.

Genprex's total operating income in 2025 was -$15.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $15.52 million

Over the last 9 years, Genprex's total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, Genprex's cash and equivalents has ranged from $1.10 million in Q3 2025 to $18.05 million in Q1 2026, and is currently $18.05 million as of their latest financial filing in Q1 2026.

Genprex had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2016.

Over the last 9 years, Genprex's book value per share changed from 0.15 in 2016 to 3.51 in 2025, a change of 2,237.9%.



Financial statements for NASDAQ:GNPX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners